Clindamycin is the drug of choice in -
In general, B. fragilis is susceptible to metronidazole, carbapenems, tigecycline, beta-lactam/beta-lactamase inhibitor combinations (e.g., Unasyn, Zosyn), and ceain antimicrobials of the cephalosporin class, including cefoxitin. The bacteria have inherent high-level resistance to penicillin. Production of beta lactamase appears to be the main mechanism of antibiotic resistance in B. fragilis. Clindamycin is no longer recommended as the first-line agent for B. fragilis due to emerging high-level resistance (>30% in some repos) Ref Harrison20th edition pg 1079
Methicillin resistance Staph. Aureus
Mycoplasma pneumoniae
Bacteroidis fragilis
Pseudomonus infection
Infection